vimarsana.com
Home
Live Updates
ITM Isotope Technologies Munich SE: ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma : vimarsana.com
ITM Isotope Technologies Munich SE: ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
Garching/Munich, Munich and Münster, Germany, March 13, 2023 - ITM Isotope Technologies Munich SEand the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster today announced
Related Keywords
Germany ,
Neuherberg ,
Bayern ,
Garching ,
Munich ,
Dennis Riedl ,
Reinhard Zeidler ,
Ben Orzelek ,
Walter Stummer ,
Thomas Bauer ,
Verena Coscia ,
Steffen Schuster ,
Julia Hofmann Svenja ,
Department Of Neurosurgery ,
University Hospital ,
Nuclear Medicine ,
Corporate Communications ,
Helmholtz Association ,
Technologies Munich ,
Targeted Radionuclide Therapy ,
Helmholtz Munich ,
Radionuclide Therapy ,
Prof Walter Stummer ,
Principal Investigator ,
Project Leader ,
Brain Tumor ,
Isotope ,
Technologies ,
Helmholtz ,
University ,
Hospital ,
M 252 Nster ,
Nnounce ,
Start ,
Hase ,
Linical ,
Trial ,
Adiotherapeutic ,
Glioblastoma ,
vimarsana.com © 2020. All Rights Reserved.